KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.

Yan Ji, Claudio Calonder, Tiina Kirsiläe, Alis Burciu, Nathalie Laurent, Eva Hua, Thomas Severin, Manmath Patekar, Ralph Woessner

Clin Transl Sci 19(7) e70661

PMID42443720
PMCIDPMC13364750
DOI10.1111/cts.70661
发表日期2026-07-13
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

Ligelizumab is a highly potent, humanized IgG1 anti-IgE monoclonal antibody that was developed to treat chronic spontaneous urticaria (CSU). The immunogenicity of ligelizumab and its clinical impact were investigated in CSU patients following subcutaneous administration of 72 or 120 mg ligelizumab once every 4 weeks based on pooled data from two pivotal phase 3 clinical trials (PEARL-1 and PEARL-2). Across the 72 mg ligelizumab, 120 mg ligelizumab and placebo transitioned 120 mg ligelizumab arms, treatment-emergent anti-drug antibodies (TE-ADAs) were observed in 20.0%-22.6% of patients, out of whom 78.0%-81.7% developed neutralizing antibodies. The majority (> 99%) of patients with TE-ADAs had treatment-induced ADAs and 74.0%-90.0% developed a persistent ADA response. ADA titers became detectable in Week 12 after start of ligelizumab treatment and reached plateau around Week 20, with the median ADA onset at 143-147 days. In the 72 and 120 mg ligelizumab arms, the geometric mean steady-state trough concentration of ligelizumab was 52% and 41% lower, and the pharmacodynamic marker total IgE (% change from baseline) was 71% and 66% lower in ADA-positive than in ADA-negative patients, respectively. However, primary efficacy endpoint (change from baseline in Urticaria Activity Score 7) and key safety endpoints (incidence of treatment-emergent hypersensitivity and injection-site reactions) did not show clinically meaningful difference between ADA-positive and ADA-negative patients. This comprehensive analysis is the first report characterizing the immunogenicity profile of ligelizumab. The results indicate that ADAs reduced ligelizumab pharmacokinetic exposure and target engagement but had no clinically relevant impact on efficacy or safety in patients with CSU.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Titer distribution in ADA‐positive samples of CSU patients in the treatment group of ligelizumab 72 mg (a), ligelizumab 120 mg (b), and placebo‐ligelizumab 120 mg transitioned (c). Circles present means; hyphens in the boxes present medians; filled dots denote outliers; whiskers mark Q1‐1.5*IQR and Q3 + 1.5 × IQR, respectively; numbers displayed above each boxplot represent n / N (%), with n indicating the number of ADA‐positive patients at the specified sampling time point, N denoting the total number of patients evaluable for immunogenicity, and with % providing the corresponding ADAprevalence; IQR, interquartile range; Q, quartile.
非 KM Figure
FIGURE 2FIGURE 2 Steady‐state ligelizumab trough concentration (a) and total IgE percentage change from baseline (b) in the presence or absence of treatment‐emergent ADAs in CSU patients. Filled dots present outliers; circles present means; hyphens in the boxes present medians; whiskers present Q1‐1.5 × IQR and Q3 + 1.5 × IQR, respectively; IQR, interquartile range; Q, quartile.
非 KM Figure
FIGURE 3FIGURE 3 Summary of UAS7 change from baseline by visit and treatment‐emergent (TE) ADA status in the treatment group of ligelizumab 72 mg (a), ligelizumab 120 mg (b), and placebo‐ligelizumab 120 mg transitioned (c). Filled dots present outliers; circles present means; hyphens in the boxes present medians; whisker presents Q1‐1.5 × IQR and Q3 + 1.5 × IQR, respectively; numbers displayed above each boxplot represent the number of patients with available UAS7 data at both baseline and the respective post‐baseline visit within each treatment‐emergent ADA status group; IQR, interquartile range; Q, quartile.
非 KM Figure